NASDAQ · PRE
Healthcare · Medical - Diagnostics & Research
$23.66
Down-$0.61 (-2.51%)
Updated Sep 11, 2026, 3:20 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PRE closed at $23.66 after 20 trading sessions, up 20.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $24.09 | $24.70 | $23.34 | $23.66 | 188.22K |
| Sep 9, 2026 | $25.50 | $25.955 | $23.93 | $24.27 | 251.71K |
| Sep 8, 2026 | $25.44 | $26.40 | $25.41 | $25.62 | 157.89K |
| Sep 4, 2026 | $25.63 | $26.02 | $25.13 | $25.44 | 105.97K |
| Sep 3, 2026 | $26.26 | $26.58 | $25.11 | $25.63 | 203.5K |
| Sep 2, 2026 | $25.96 | $27.24 | $25.65 | $26.05 | 336.49K |
| Sep 1, 2026 | $26.46 | $26.46 | $25.01 | $25.81 | 181.54K |
| Aug 31, 2026 | $25.84 | $26.70 | $25.76 | $26.25 | 196.92K |
| Aug 28, 2026 | $26.25 | $26.29 | $25.07 | $25.76 | 273.75K |
| Aug 27, 2026 | $25.55 | $26.50 | $24.62 | $26.25 | 952.68K |
| Aug 26, 2026 | $23.80 | $26.29 | $23.29 | $25.78 | 823.11K |
| Aug 25, 2026 | $22.17 | $23.50 | $22.00 | $23.25 | 526.5K |
| Aug 24, 2026 | $19.13 | $21.88 | $19.13 | $21.82 | 417.69K |
| Aug 21, 2026 | $17.40 | $20.50 | $17.40 | $20.20 | 329.14K |
| Aug 20, 2026 | $18.76 | $19.195 | $17.81 | $17.97 | 104.55K |
| Aug 19, 2026 | $19.62 | $19.94 | $18.275 | $18.76 | 133.72K |
| Aug 18, 2026 | $19.60 | $19.76 | $18.12 | $19.40 | 297.04K |
| Aug 17, 2026 | $19.66 | $20.50 | $19.27 | $19.37 | 221.04K |
| Aug 14, 2026 | $20.00 | $20.00 | $19.25 | $19.75 | 96.75K |
| Aug 13, 2026 | $18.62 | $20.57 | $18.26 | $19.70 | 249.43K |
The latest Smart Investors Daily articles mentioning PRE.
PRE research
Company profile and research snapshot.
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | B. Riley Securities | Buy | — |
| Jul 15, 2026 | Benchmark | Buy | — |
| Jun 16, 2026 | Benchmark | Buy | — |
| Mar 16, 2026 | Lake Street | Buy | — |
| Oct 29, 2025 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
B. Riley Securities analyst Jeff Van Sinderen initiates coverage on Prenetics Global (NASDAQ:PRE) with a Buy rating and announces Price Target of $37.
Benzinga · Aug 26, 2026
Danny Yeung, Chief Executive OfficerPurchased 24,681 shares for approximately $502,000, at an average price of roughly $20.34 per share, across purchases on August 20 and August 24, 2026. This brings his cumulative
SeekingAlpha · Aug 24, 2026
Prenetics (PRE) stock analysis: IM8 growth to 140k subs, AI-driven marketing, and General Catalyst CAC financing.
SeekingAlpha · Aug 22, 2026
Prenetics Global Limited (PRE) Q2 2026 Earnings Call August 18, 2026 8:30 AM EDTCompany ParticipantsSheng Wu Yeung - Co-Founder, Chairperson & CEOBrian...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRE.
